POST STROKE BRAIN RECOVERY TARGETING BLOOD FLOW AND VESSEL HEALTH
Dr Daniel Beard,
Senior Lecturer, University of Newcastle
Group Leader, Neurovascular Research Laboratory
New South Wales, Australia &
Visiting Scientist,
University of Oxford, United Kingdom &
Founder and Chief Scientific Officer
ShearFlow
RESEARCHER PROFILE
Filmed in Newcastle, Australia | May 2026
Dr Daniel Beard is a Senior Lecturer and Group Leader of the Neurovascular Research Laboratory at the University of Newcastle, with a distinguished career in stroke research. Dr Beard completed his PhD in Human Physiology in 2015, uncovering the impact of intracranial pressure on collateral vessel failure. He has held prestigious research and teaching roles at the University of Oxford and Charité Universitätsmedizin Berlin, contributing to international collaborations on neurovascular protection. His research has been supported by competitive grants, including an NHMRC Ideas Grant, and he has received numerous awards for innovation, research excellence and teaching excellence, including:
-Winner of the Challenger Pitch Prize at the Proto Axiom Challenger Summit (2024).
-Paul Dudley White International Scholar for the highest-ranked Australian abstract at the 2022 International Stroke Conference, New Orleans.
-Recipient of the Learning Design and Teaching Innovation Teaching Excellence Award and Mid-Career Teaching Award from the University of Newcastle (2024).
His most recent work focuses on understanding and improving collateral blood flow during ischaemic stroke. Notably, his groundbreaking work on shear stress and cerebral blood flow with renowned researchers at Harvard University, resulted in a patented nanoparticle therapy that selectively boosts brain perfusion during stroke, saving brain tissue and improving patient outcomes. This work was recently published in Advanced Science: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506276.
Dr Beard is Founder and Chief Scientific Officer of the University spinout ShearFlow that is now commercializing this technology to reach the clinic. This work aims to deliver targeted stroke therapies that could give patients a improved chance at recovery and a better quality of life.
Source: Supplied and adapted
https://orcid.org/0000-0002-3720-7588
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
